Oaktree Exits 5%+ Stake in Indivior, Sells 6.5M Shares

summarizeSummary

Oaktree Capital's funds have exited their 5%+ common stock position in Indivior, selling 6.48 million shares between June 26 and August 12, 2026, and now hold only convertible notes representing 0.76% of the company.

check_boxKey Events · Ownership and Investor Activity · INDV

• Oaktree Exits 5%+ Stake

  Oaktree funds ceased to be beneficial owners of more than 5% of Indivior common stock on or prior to August 10, 2026, triggering this exit filing.

• 6.48M Shares Sold

  Between June 26 and August 12, 2026, Oaktree sold 6,477,212 shares at prices ranging from $37.75 to $42.13, with the largest single sale of 4.54 million shares on August 12.

• Convertible Notes Remain

  Oaktree still holds $37.872 million principal amount of 0.625% Convertible Senior Notes due 2031, convertible into 909,053 shares (0.76% of outstanding).

• Timing Coincides with Merger

  The exit comes just days after Indivior announced an all-stock merger of equals with Supernus Pharmaceuticals on August 3, 2026.

auto_awesomeAnalysis · INDV · Life Sciences

Oaktree Capital's funds have sold down their entire common stock position in Indivior, dropping below the 5% reporting threshold. The sales occurred between June 26 and August 12, 2026, at prices ranging from $37.75 to $42.13, totaling approximately 6.48 million shares. This is a significant exit by a major institutional holder, coming just days after Indivior announced a merger of equals with Supernus Pharmaceuticals. The timing suggests Oaktree may be reducing exposure ahead of the merger or taking profits after a strong run in the stock. The remaining position is now only in convertible notes, representing less than 1% of the company.